Cardiac transthyretin amyloidosis treatment improves outcomes after aortic valve replacement for severe stenosis

Abstract

ATTR-specific treatment and AVR both result in significant survival benefit in dual pathology AS and ATTR-CA. Results should be interpreted in the context of the non-randomized study setting and differences in patient characteristics.